Search Follow us
Refine By

Stock Exchange


Type of Publication


1 - 3 of 3
Sort by: popularity | newest
Page  of 1
ASLAN Pharmaceuticals

Additional clinical support for varlitinib

Update | Pharmaceutical & healthcare | 07 Jun 2018

ASLAN presented data at ASCO from a Phase Ib dosing study examining varlitinib in combination with carboplatin, paclitaxel and Herceptin. Patients were enrolled across a range of cancers, but the majority (20/37) were HER2+ metastatic breast cancer patients. The drug demonstrated efficacy across the study and the addition of Herceptin at the optimal dose did not induce toxicity, suggesting the potential of future combinations.

ASLAN Pharmaceuticals

ASLAN acquires full rights to varlitinib

Update | Pharmaceutical & healthcare | 10 Jan 2018

In January 2018, ASLAN announced that it had fully acquired the global commercial rights to varlitinib from its partner, Array BioPharma. Previously, the agreement stipulated that ASLAN develop the drug and sublicense it, and we view the current agreement as a significant improvement. We believe that ASLAN brings significant value to the table in Asian development capacity. The licence is now consistent with the goal of directly commercialising varlitinib in the US and parts of Asia.

ASLAN Pharmaceuticals

Novel treatments for worldwide unmet needs

Initiation | Pharmaceutical & healthcare | 07 Nov 2017

We are initiating coverage on ASLAN Pharmaceuticals, a clinical-stage drug developer focusing on in-licensing drugs with a high prevalence in Asia that are orphan indications in the West. The company's lead asset is the pan-HER inhibitor varlitinib, which is in clinical trials for biliary tract cancer (BTC, pivotal) and gastric cancer (GC, Phase II/III), both of which are widely prevalent in Asia. The company has also planned a Phase II trial of ASLAN003 targeting AML via the novel mechanism of inducing blast differentiation. We initiate at NT$9.5bn or NT$72.87 per share.